Untitled

Hanief, M.; Igali, Laszlo; Grama, D

doi:10.1186/1477-7819-2-27

Cited by 13 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTC was the most common type of DTC associated with PM in our study; PTC is the main contributor to the rising incidence of thyroid cancers globally [ 40 ]. It is interesting to note that HCC, which has been reported to have the highest incidence of metastases among DTC, was least frequently described with PM in our review [ 41 ].…”

Section: Discussionmentioning

confidence: 97%

Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Background Pituitary metastasis (PM) from differentiated thyroid cancer (DTC) is extremely rare and may adversely affect outcomes. We aimed to assess the characteristics and outcomes of patients with PM from DTC. Methods We systematically reviewed the literature on publications on PM and the different DTC histologic types (papillary, follicular, and Hurthle cell cancers). Three databases (PubMed, Embase, and Scopus) were searched for articles published from 1967 to 2022. Survival time was estimated as the period from the first treatment of PM to the time of death or last follow-up. Results Twenty-five articles comprising 27 cases that met the eligibility criteria were identified using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The median age of the patients was 60 years (23 - 86). A preponderance of females (66.7%) with PM most commonly reported papillary thyroid cancer (55.6%). This was followed by follicular thyroid cancer (37.0%) and Hurthle cell cancer (7.4%). The most common presentations were headache, nausea, and vomiting, with visual symptoms in 44.4%. Diabetes insipidus was an infrequent finding (7.4%). The median time from diagnosis or first treatment of DTC to the diagnosis of PM was 3 years (0 - 25). The most common endocrine abnormality was hyperprolactinemia (63.2%), while the most frequently deficient hormone was luteinizing hormone (50%). The most common treatment modality for PM was a combination of radiotherapy and surgery with or without radio-iodine. At the end of the follow-up, 30% of the patients died. Only 33.3% of the patients achieved complete resolution of symptoms. The overall median survival time was 12 months (3 - 108). There was a moderate inverse correlation between the age of patients and survival, which was, however, not statistically significant (rs = -0.45, P = 0.103). Conclusion PM from DTC is extremely rare, and Hurtle cell cancer appears to be the least associated with PM. Diabetes insipidus is a rare initial manifestation of PM from DTC. Complete resolution of symptoms is less likely to be achieved in PM from DTC. Older age may confer an increased survival tendency, probably due to more intracranial space volume in older people compared to the younger population. Larger studies are needed to examine the relationship between age and survival in PM from DTC. Also, more observational data are required to determine the predictors of survival and compare the efficacy of the different treatment modalities in patients with PM from DTC.

show abstract

Section: Discussionmentioning

confidence: 97%

Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Thyroidectomy facilitates postoperative radioactive iodine treatment, and adequate treatment reduces the likelihood of recurrence. Surgical dissection of cervical lymph nodes is dependent on the patterns of disease spread and cancer stage [ 20 , 22 ]. Larger tumors (>T2) require total thyroidectomy and lymphadenectomy if lymph nodes are involved.…”

Section: Discussionmentioning

confidence: 99%

Oncocytic Cell Carcinoma of the Thyroid: A Case Report and an Overview of the Diagnosis, Treatment Modalities, and Prognosis

Syed¹,

Vanka²,

Escudero³

et al. 2022

Cureus

View full text Add to dashboard Cite

Cancers of the thyroid gland are uncommon, accounting for 1% of malignant tumors. Oncocytic carcinoma of the thyroid (OCA), previously known as "Hürthle cell" carcinomas, make up 3% to 5% of all thyroid cancers and are extremely rare. In the United States, the incidence of thyroid cancer is approximately 12 per 100,000 per year and increases with age. The prevalence of thyroid cancers in women is estimated to be twice that in men, with the male gender correlating with a worse prognosis.A definitive diagnosis of OCA is confirmed after complete excision and histopathological examination. OCA is an aggressive tumor with an exceedingly low incidence, a high risk of metastasis, and a poor prognosis. The mainstay of therapy for OCA is surgery. In order to recognize and treat the disease as early as possible, healthcare providers must consider the probability of OCA in patients presenting with a thyroid mass.We hereby present a case of OCA identified incidentally status post tracheostomy and subsequent biopsy. We have an opportunity to review this disease with the hope of improving outcomes by raising awareness and with early recognition.

show abstract

“…Metastases to the pituitary gland are uncommon and, when they do occur, are usually from either a lung or breast primary 1. HCC has the highest rate of metastasis among all the DTCs, predominantly to lymph nodes and the lung 2. Rarely does a DTC metastasise to the pituitary.…”

Section: Introductionmentioning

confidence: 99%

Pituitary metastases of Hürthle cell carcinoma of the thyroid

et al. 2021

View full text Add to dashboard Cite

An 85-year-old man was referred to endocrinology following the discovery of an incidental pituitary mass on cranial imaging which was thought to be a non-functioning adenoma during an admission with headaches, lethargy, confusion and hyponatraemia. He had a history of Hürthle cell carcinoma of the thyroid treated with total thyroidectomy, ablative radioiodine therapy and thyroxine replacement. Subsequently, he developed metastatic spread to the neck, lungs and skeleton. About 9 months later, the patient had deterioration of vision. MRI showed a rapidly expanding pituitary mass with compression of the optic chiasm. Biochemical investigations confirmed hypocortisolism and hypogonadism. The patient underwent trans-sphenoidal resection of the pituitary mass followed by external beam radiotherapy to the pituitary bed. Histopathology confirmed a metastatic deposit of Hürthle cell carcinoma, which is a rare and aggressive variant of follicular thyroid carcinoma.

show abstract

Untitled

Abstract: Background: Hürthle cell carcinoma is a variant of follicular cell carcinoma of thyroid. It may present as a low-grade tumour or as a more aggressive type. Prognosis depends upon the age of the patient, tumour size, extent of invasion and initial nodal or distant metastasis.

Cited by 13 publications

References 26 publications

Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review

Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review

Oncocytic Cell Carcinoma of the Thyroid: A Case Report and an Overview of the Diagnosis, Treatment Modalities, and Prognosis

Pituitary metastases of Hürthle cell carcinoma of the thyroid

Contact Info

Product

Resources

About